NO328824B1 - Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. - Google Patents
Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. Download PDFInfo
- Publication number
- NO328824B1 NO328824B1 NO20001508A NO20001508A NO328824B1 NO 328824 B1 NO328824 B1 NO 328824B1 NO 20001508 A NO20001508 A NO 20001508A NO 20001508 A NO20001508 A NO 20001508A NO 328824 B1 NO328824 B1 NO 328824B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- tat
- nef
- hiv
- derivative
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 89
- 102000004169 proteins and genes Human genes 0.000 title claims description 81
- 239000000203 mixture Substances 0.000 title claims description 29
- 229960005486 vaccine Drugs 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 20
- 108020004707 nucleic acids Proteins 0.000 title claims description 9
- 102000039446 nucleic acids Human genes 0.000 title claims description 9
- 150000007523 nucleic acids Chemical class 0.000 title claims description 9
- 108020001507 fusion proteins Proteins 0.000 title description 22
- 102000037865 fusion proteins Human genes 0.000 title description 17
- 238000002360 preparation method Methods 0.000 title description 5
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 title description 4
- 108091005461 Nucleic proteins Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 101710149951 Protein Tat Proteins 0.000 claims description 50
- 230000004927 fusion Effects 0.000 claims description 25
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 16
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
- 241000235058 Komagataella pastoris Species 0.000 claims description 13
- 238000007792 addition Methods 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 9
- 101710188053 Protein D Proteins 0.000 claims description 9
- 101710132893 Resolvase Proteins 0.000 claims description 9
- 108090001030 Lipoproteins Proteins 0.000 claims description 8
- 102000004895 Lipoproteins Human genes 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 claims description 7
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 5
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000007764 o/w emulsion Substances 0.000 claims description 5
- 229940031439 squalene Drugs 0.000 claims description 5
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 64
- 235000001014 amino acid Nutrition 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- 238000010367 cloning Methods 0.000 description 18
- 238000010276 construction Methods 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 235000014304 histidine Nutrition 0.000 description 13
- 101710192141 Protein Nef Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
- 239000004473 Threonine Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 108700004028 nef Genes Proteins 0.000 description 4
- 101150023385 nef gene Proteins 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 108700004027 tat Genes Proteins 0.000 description 4
- 101150098170 tat gene Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710204610 Envelope glycoprotein gp160 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- -1 MnCh Chemical compound 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100525628 Picea mariana SB62 gene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9720585.0A GB9720585D0 (en) | 1997-09-26 | 1997-09-26 | Vaccine |
PCT/EP1998/006040 WO1999016884A1 (fr) | 1997-09-26 | 1998-09-17 | Proteines de fusion comprenant les proteines tat et/ou nef du vih-1 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20001508D0 NO20001508D0 (no) | 2000-03-23 |
NO20001508L NO20001508L (no) | 2000-05-18 |
NO328824B1 true NO328824B1 (no) | 2010-05-25 |
Family
ID=10819735
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001508A NO328824B1 (no) | 1997-09-26 | 2000-03-23 | Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. |
NO20076467A NO20076467L (no) | 1997-09-26 | 2007-12-14 | Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076467A NO20076467L (no) | 1997-09-26 | 2007-12-14 | Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1015596B2 (fr) |
JP (2) | JP2001518300A (fr) |
KR (1) | KR100554487B1 (fr) |
CN (1) | CN1188519C (fr) |
AR (2) | AR017147A1 (fr) |
AT (1) | ATE338128T1 (fr) |
AU (1) | AU746564B2 (fr) |
BR (1) | BR9812547A (fr) |
CA (1) | CA2305013C (fr) |
CO (1) | CO4810339A1 (fr) |
CZ (1) | CZ302878B6 (fr) |
DE (1) | DE69835756T3 (fr) |
DK (1) | DK1015596T4 (fr) |
ES (1) | ES2272012T5 (fr) |
GB (1) | GB9720585D0 (fr) |
HK (1) | HK1030431A1 (fr) |
HU (1) | HUP0004896A3 (fr) |
IL (1) | IL135102A0 (fr) |
NO (2) | NO328824B1 (fr) |
NZ (1) | NZ503482A (fr) |
PL (1) | PL195243B1 (fr) |
PT (1) | PT1015596E (fr) |
SA (1) | SA98190877B1 (fr) |
SI (1) | SI1015596T2 (fr) |
TR (1) | TR200000864T2 (fr) |
TW (1) | TW499436B (fr) |
WO (1) | WO1999016884A1 (fr) |
ZA (1) | ZA988789B (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
AU3158900A (en) * | 1999-02-25 | 2000-09-14 | Smithkline Beecham Biologicals (Sa) | Immunogens comprising a peptide and a carrier derived from h.influenzae protein |
DE60031260T2 (de) * | 1999-04-12 | 2007-05-03 | Heart Biosystems Gmbh | Vorübergehend-immortalisierte zellen zur verwendung in gentherapie |
EP1198249B1 (fr) * | 1999-06-29 | 2005-10-19 | GlaxoSmithKline Biologicals S.A. | Utilisation de cpg comme adjuvant de vaccin contre le vih |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
EP1251870A2 (fr) * | 2000-01-31 | 2002-10-30 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Nouvelle utilisation |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
EP1279404A1 (fr) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
EP1944043A1 (fr) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation. |
EP3108899A1 (fr) | 2001-11-21 | 2016-12-28 | The Trustees of the University of Pennsylvania | Séquences d'acide aminé et d'acide nucléique adsv1 adénovirus simien, vecteurs les contenant et procédés d'utilisation |
KR100466382B1 (ko) * | 2002-01-08 | 2005-01-14 | 주식회사 엘지생명과학 | 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트 |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
PL372092A1 (en) | 2002-05-16 | 2005-07-11 | Bavarian Nordic A/S | Fusion protein of hiv regulatory/accessory proteins |
GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
WO2005090968A1 (fr) | 2004-03-16 | 2005-09-29 | Inist Inc. | Compositions immunomoduatrices a base de tat, leur decouverte et leur utilisation |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
GB0507003D0 (en) * | 2005-04-06 | 2005-05-11 | Molmed Spa | Therapeutic |
KR101441843B1 (ko) | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법 |
CA2964396A1 (fr) | 2007-11-28 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Adenovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci |
BRPI0819774A2 (pt) | 2007-11-28 | 2014-10-14 | Univ Pennsylvania | Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos |
EP2325298B1 (fr) | 2008-03-04 | 2016-10-05 | The Trustees Of The University Of Pennsylvania | ADENOVIRUS DE SINGE SAdV-36, -42.1, -42.2, AND -44 ET LEUR UTILISATION |
AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
DK2313496T3 (en) | 2008-07-21 | 2014-12-15 | Taiga Biotechnologies Inc | Anukleære differentiated cells, and method for preparation thereof |
AU2009285547B2 (en) | 2008-08-28 | 2012-05-31 | Taiga Biotechnologies (Abc), Llc | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
ES2552688T3 (es) | 2008-10-31 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo |
US8530431B2 (en) | 2009-03-23 | 2013-09-10 | Pin Pharma, Inc. | Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides |
CN102575232B (zh) | 2009-05-29 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿腺病毒41及其应用 |
AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
EP2708561A4 (fr) * | 2011-03-15 | 2014-09-24 | Univ Yonsei Iacf | Bio-aiguille |
CN105473723A (zh) | 2012-05-18 | 2016-04-06 | 宾夕法尼亚大学托管会 | 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途 |
WO2014012090A1 (fr) * | 2012-07-13 | 2014-01-16 | The Broad Institute, Inc. | Traîneaux moléculaires comprenant une séquence d'acides aminés à charges positives et cargaison moléculaire et utilisations correspondantes |
US9789135B2 (en) | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
AU2014329393B2 (en) | 2013-10-04 | 2020-04-30 | Pin Pharma, Inc. | Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment |
CR20160519A (es) | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
US11207421B2 (en) | 2015-04-16 | 2021-12-28 | The Research Foundation For The State University Of New York | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags |
AU2016248454B2 (en) * | 2015-04-16 | 2020-05-14 | Path | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags |
CA3045017A1 (fr) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Formulations de nanoparticules |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
IL308404A (en) | 2021-04-27 | 2024-01-01 | Generation Bio Co | Non-viral DNA vectors expressing therapeutic antibodies and uses thereof |
WO2023177655A1 (fr) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9003010D0 (en) * | 1990-02-09 | 1990-04-04 | Glaxo Group Ltd | Gene expression in yeast cells |
EP0625052A4 (fr) * | 1991-10-21 | 1995-07-19 | Medimmune Inc | Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines. |
CA2135642C (fr) * | 1992-08-21 | 1999-12-14 | James G. Barsoum | Polypeptides de transport derives de la proteine tat |
ATE302854T1 (de) * | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
PL322143A1 (en) * | 1995-03-08 | 1998-01-05 | Neovacs | Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
-
1997
- 1997-09-26 GB GBGB9720585.0A patent/GB9720585D0/en not_active Ceased
-
1998
- 1998-09-17 HU HU0004896A patent/HUP0004896A3/hu unknown
- 1998-09-17 CZ CZ20001091A patent/CZ302878B6/cs not_active IP Right Cessation
- 1998-09-17 WO PCT/EP1998/006040 patent/WO1999016884A1/fr active IP Right Grant
- 1998-09-17 JP JP2000513953A patent/JP2001518300A/ja not_active Withdrawn
- 1998-09-17 SI SI9830860T patent/SI1015596T2/sl unknown
- 1998-09-17 ES ES98952625T patent/ES2272012T5/es not_active Expired - Lifetime
- 1998-09-17 CA CA002305013A patent/CA2305013C/fr not_active Expired - Fee Related
- 1998-09-17 EP EP98952625A patent/EP1015596B2/fr not_active Expired - Lifetime
- 1998-09-17 DE DE69835756T patent/DE69835756T3/de not_active Expired - Lifetime
- 1998-09-17 IL IL13510298A patent/IL135102A0/xx not_active IP Right Cessation
- 1998-09-17 KR KR1020007003180A patent/KR100554487B1/ko not_active IP Right Cessation
- 1998-09-17 AU AU10255/99A patent/AU746564B2/en not_active Ceased
- 1998-09-17 PT PT98952625T patent/PT1015596E/pt unknown
- 1998-09-17 AT AT98952625T patent/ATE338128T1/de active
- 1998-09-17 TR TR2000/00864T patent/TR200000864T2/xx unknown
- 1998-09-17 NZ NZ503482A patent/NZ503482A/en not_active IP Right Cessation
- 1998-09-17 DK DK98952625.6T patent/DK1015596T4/da active
- 1998-09-17 CN CNB988114321A patent/CN1188519C/zh not_active Expired - Fee Related
- 1998-09-17 BR BR9812547-8A patent/BR9812547A/pt not_active IP Right Cessation
- 1998-09-17 PL PL98339432A patent/PL195243B1/pl not_active IP Right Cessation
- 1998-09-24 AR ARP980104779A patent/AR017147A1/es active IP Right Grant
- 1998-09-25 ZA ZA9808789A patent/ZA988789B/xx unknown
- 1998-09-25 CO CO98056054A patent/CO4810339A1/es unknown
- 1998-10-22 TW TW087117493A patent/TW499436B/zh not_active IP Right Cessation
- 1998-12-15 SA SA98190877A patent/SA98190877B1/ar unknown
-
2000
- 2000-03-23 NO NO20001508A patent/NO328824B1/no not_active IP Right Cessation
- 2000-12-27 HK HK00108429A patent/HK1030431A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 NO NO20076467A patent/NO20076467L/no unknown
-
2009
- 2009-06-30 JP JP2009155916A patent/JP2009213492A/ja active Pending
-
2011
- 2011-02-28 AR ARP110100606A patent/AR080331A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO328824B1 (no) | Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. | |
KR101501495B1 (ko) | Hiv-감염의 예방 및 치료를 위한 백신 | |
JP2003529559A (ja) | 新規用途 | |
KR20100109555A (ko) | 백신 | |
SG184188A1 (en) | Hiv vaccine | |
US20100215681A1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
MXPA00002973A (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |